ArticlePloS one2013
Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- First-in-Man Evaluation ofMolecular imagingTrial
- Insights into programmed cell death from multiple imaging modalities.Journal of translational medicine · 2026Review
- Radionuclide imaging of apoptosis for clinical application.European journal of nuclear medicine and molecular imaging · 2022Review
- Apoptosis Imaging in Oncology by Means of Positron Emission Tomography: A Review.International journal of molecular sciences · 2021Review
- Avenues to molecular imaging of dying cells: Focus on cancer.Medicinal research reviews · 2018Review
- PSP1, a Phosphatidylserine-Recognizing Peptide, Is Useful for Visualizing Radiation-Induced Apoptosis in Colorectal Cancer In Vitro and In Vivo.Translational oncology · 2018Article
- Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.ImmunoTargets and therapy · 2018Review
- Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential.Molecular imaging · 2017Article
- Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.Cancers · 2016Review
- Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.Investigational new drugs · 2015Article
- Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold.Bioconjugate chemistry · 2015Article
- Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.American journal of nuclear medicine and molecular imaging · 2015Article
- Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- Chromatographic separation of selenium and arsenic: A potential (72)Se/(72)As generator.Journal of chromatography. A · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Phosphatidylserine (PS) is an attractive target for imaging agents that identify tumors and assess their response to therapy. PS is absent from the surface of most cell types, but becomes exposed on tumor cells and tumor vasculature in response to oxidative stresses in the tumor microenvironment and increases in response to therapy. To image exposed PS, we used a fully human PS-targeting antibody fragment, PGN635 F(ab')2, that binds to complexes of PS and β2-glycoprotein I. PGN635 F(ab')2 was labeled with the positron-emitting isotope iodine-124 ((124)I) and the resulting probe was injected into nude mice bearing subcutaneous or orthotopic human PC3 prostate tumors. Biodistribution studies showed that (124)I-PGN635 F(ab')2 localized with remarkable specificity to the tumors with little uptake in other organs, including the liver and kidneys. Clear delineation of the tumors was achieved by PET 48 hours after injection. Radiation of the tumors with 15 Gy or systemic treatment of the mice with 10 mg/kg docetaxel increased localization in the tumors. Tumor-to-normal (T/N) ratios were inversely correlated with tumor growth measured over 28 days. These data indicate that (124)I-PGN635 F(ab')2 is a promising new imaging agent for predicting tumor response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.